Señales en vivo de PMN.TO | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (21 jul 2023 @ 15:55):

Stats
Volumen de hoy	19 701.00
Volumen promedio	5 307.00
Capitalización de mercado	51.48M
EPS	$0 ( 2024-03-06 )
Próxima fecha de ganancias	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.775
ATR14	$0.302 (5.03%)

Volumen Correlación

Largo: -0.03 (neutral)

Corto: 0.88 (strong)

Signal:(53.495) Same movement expected

ProMIS Neurosciences Inc Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

ProMIS Neurosciences Inc Correlación - Moneda/Commodity

0.17
( neutral )

-0.41
( neutral )

-0.51
( weak negative )

0.22
( neutral )

-0.21
( neutral )

0.53
( weak )

ProMIS Neurosciences Inc Finanzas

Annual	2022
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$-1.680

FY	2022
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$-1.680

FY	2021
Ingresos:	$16 410.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-2.04

FY	2020
Ingresos:	$1 787.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-1.190

Financial Reports:

No articles found.

ProMIS Neurosciences Inc

ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.